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Purpose
Although the use of xenograft models is increasing, few studies have compared the clinical
features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumori-
genicity of engrafted specimens. The purpose of this study was to evaluate whether tumori-
genicity was associated with the clinical features and outcomes of EOC patients. 
Materials and Methods
Eighty-eight EOC patients who underwent primary or interval debulking surgery from June
2014 to December 2015 were included. Fresh tumor specimens were implanted subcuta-
neously on each flank of immunodeficient mice. Patient characteristics, progression-free sur-
vival (PFS), and germline mutation spectra were compared according to tumorigenicity.
Results
Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was 
associated with lymphovascular invasion and there was a propensity to engraft successfully
with high-grade tumors. Tumors from patients who underwent non-optimal (residual disease
 1 cm) primary or interval debulking surgery had a significantly greater propensity to achieve
tumorigenicity than those who received optimal surgery. In addition, patients whose tumors
became engrafted seemed to have a shorter PFS and more frequent germline mutations
than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for pre-
dicting PFS with advanced International Federation of Gynecology and Obstetrics stage and
high-grade cancers.
Conclusion
Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with
more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical
tool to predict prognosis and could be applied to further pharmacologic and genomic studies
on personalized treatments.
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Introduction
Epithelial ovarian cancer (EOC) remains a leading cause
of gynecologic cancer-related mortality because it exhibits
marked heterogeneity at the molecular, cellular, and clinical
levels. This results in a high recurrence rate after standard
primary treatment [1,2]. To deal with the heterogeneity, per-
sonalized medicine is now widely considered for intractable
EOC, and its possible value is a reason for global research on
this approach [3].
To precisely represent the biologic characteristics of an 
individual patient, previous studies have established disease
models including two-dimensional cell lines and patient-
derived xenograft models [4,5]. Compared with cancer cell
lines, xenograft models can better characterize features of the
original tumor, including tumor heterogeneity [6,7]. There-
fore, xenograft models have become a widely used preclini-
cal tool for developing treatment strategies in refractory EOC
[2,8].
The rate of successful tumorigenicity of cancer specimens
from EOC patients has been variable in previous studies.
Furthermore, a considerable proportion of tumor samples
failed to engraft successfully in xenograft models [9,10]. Suc-
cessful engraftment may reflect aggressiveness of the pri-
mary tumor. Although the use of xenograft models has been
increasing, few studies have compared the clinical features
and outcomes of EOC patients according to tumorigenicity
of the engrafted specimens [9-11]. Investigation of the rela-
tionship between engraftment tumorigenicity and EOC path-
ogenicity may provide better insight into the interpretation
of findings of preclinical studies using xenograft models.
Thus, the present study was designed to determine whether
tumorigenicity correlates with the clinical features and out-
comes of EOC patients. 
Materials and Methods
1. Patients
Eighty-eight patients who were diagnosed with EOC from
June 2014 to December 2015 were enrolled in this study. 
Included patients underwent one of the following two types
of surgeries: (1) primary cytoreductive and (2) interval 
debulking following diagnostic laparoscopy. 
2. Establishment of an ovarian cancer xenograft model
Fresh tumor tissues from consenting patients with ovarian
cancer were collected at the time of debulking (primary or
interval) surgery. Samples were minced into small fragments
with an operating scissors in RPMI 1640 medium (LM011-03,
Welgene, Gyeongsan, Korea) containing a 1 antibiotic-
antimycotic solution (15240-062, Gibco, Grand Island, NY).
Tumor cells were implanted subcutaneously on each flank
of nude and NOG mice (S1 Video). Mice were anesthetized
by injection of Zoletil/Rompun (7:3 ratio) and shaved on the
rump where the surgery would occur. The site was disinfec-
ted with povidone iodine pads and 70% isopropyl alcohol
swabs. A 2-mm long incision was made in the skin at the
rump, and 100 µL of previously chopped tumor fragments
were placed into each flank using a 10-gauge trocar. After
implantation, the skin was sutured and the mice revived.
Tumor size was evaluated 2 to 3 times per week with a dig-
ital caliper (S2 Video). The tumor volume was calculated by
the formula: 1/2 (width2  length). Implants that reached a
volume of 500 mm3 were considered tumorigenic. 
The tumor from a founder mouse was expanded with a
single passage into 5 to 10 mice to generate sufficient tumor
volume for banking and future experiments. Harvested tis-
sue was cryopreserved in 1 mL cryovials using 10% dimethyl
sulfoxide for 72 hours in a 70°C freezer. After freezing, sam-
ples were transferred to liquid nitrogen tanks for a minimum
of 24 hours before thawing in a 37°C water bath.
3. Clinicopathologic analysis
Patient characteristics according to tumorigenicity of the
engrafted tumor were compared. Patients were grouped 
according to the type of surgery: (1) primary cytoreductive
including fertility-sparing and (2) diagnostic laparoscopy fol-
lowed by interval debulking. All the patients included in the
latter group received homogeneous regimen (i.e., paclitaxel
and carboplatin) as neoadjuvant chemotherapy for 3 times,
prior to interval debulking surgery. The following data were
extracted from the medical records and compared according
to the tumorigenicity: age, preoperative carbohydrate anti-
gen 125 (CA-125) level, BRCA1/2 mutation, origin of the dis-
ease, histologic type, International Federation of Gynecology
and Obstetrics (FIGO) stage, grade, lymphovascular inva-
sion, lymph node metastasis, type of surgery, American 
Society of Anesthesiologists physical status, and residual dis-
ease.
4. Comparison of germline DNA mutation spectra with 
tumorigenicity
To investigate the germline mutational status of patients
with and without tumorigenicity, we performed the next-
generation sequencing assay using a 35-multigene test panel.
We selected about ten patients from each group and deter-
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mined the germline DNA mutations of 35 genes to compare
the mutation spectra. Germline DNA was extracted from a
peripheral blood sample of the participants using the 
QIAamp Blood DNA mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Intact DNA
was quantified and adjusted to a concentration of 5 ng/µL
using a Qubit 2.0 fluorometer and the Qubit dsDNA HS
Assay Kit (Invitrogen, Waltham, MA). Pre-capture libraries
were constructed according to the manufacturer’s sample
preparation protocol. Each patient’s genomic DNA was frag-
mented with a median size of 300 bp. A customized targeted
capture sequencing panel (OncoRisk, produced by Celemics,
Seoul, Korea) was used that covered all coding sequences
and intron-exon boundaries of coding exons from 35 cancer
susceptibility genes including: BRCA1, BRCA2, PALB2,
BARD1, BRIP1, RAD51C, RAD51D, RAD50, NBN, MRE11A,
ATM, CHEK2, TP53, PTEN, APC, BLM, BMPR1A, CDH1,
CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6,
MUTYH, PMS2, POLE, PRSS1, RET, SLX4, SMAD4, STK11,
VLH, and WT1. The DNA fragments were end-repaired,
phosphorylated, and adenylated on the 3 ends. Index adap-
tors were ligated to the repaired ends, DNA fragments were
amplified, and fragments of 200 to 500 bp were isolated.
Pooled libraries were sequenced on a MiSeq sequencer (Illu-
mina, San Diego, CA) using the MiSeq Reagent Kit v2 (300
cycles).
Characteristic Total patients Tumorigenicity
(n=88) Yes (n=47) No (n=41) p-value
Age, median (range, yr) 53 (27-82) 54 (32-82) 52 (27-72) 0.460
Preoperative CA-125 level (U/mL) 1,527.2 (2-11,779) 1,157.1 (2-8,189) 1,951.5 (28-11,779) 0.439
Histology
Serous 54 (61.4) 31 (66.0) 23 (56.1) 0.594
Mucinous 4 (4.5) 3 (6.4) 1 (2.4)
Endometrioid 11 (12.5) 4 (8.5) 7 (17.1)
Clear cell 12 (13.6) 5 (10.6) 7 (17.1)
Carcinosarcoma 3 (3.4) 2 (4.3) 1 (2.4)
Squamous cell 1 (1.1) 1 (2.1) 0 (
Unknown 3 (3.4) 1 (2.1) 2 (4.9)
FIGO stage
I 11 (12.5) 6 (12.8) 5 (12.2) 0.831
II 4 (4.5) 2 (4.3) 2 (4.9)
III 52 (59.1) 26 (55.3) 26 (63.4)
IV 21 (23.9) 13 (27.7) 8 (19.5)
High-grade tumor 66 (75.0) 39 (83.0) 27 (65.9) 0.054
Lymphovascular invasion 40 (45.5) 27 (57.4) 13 (31.7) 0.016
LN metastasis 41 (46.6) 24 (51.1) 17 (41.5) 0.368
BRCA1/2 mutation 14 (15.9) 10 (21.3) 4 (9.8) 0.142
Type of surgery
Primary debulking 64 (72.7) 36 (76.6) 28 (68.3) 0.661
Interval debulking 24 (27.3) 11 (23.4) 13 (31.7)
ASA physical status
1 13 (14.8) 7 (14.9) 6 (14.6) 0.999
2 43 (48.9) 23 (48.9) 20 (48.8)
3 32 (36.4) 17 (36.2) 15 (36.6)
Residual disease
NGR 50 (56.8) 21 (44.7) 29 (70.7) 0.022
< 1 cm 26 (29.5) 16 (34.0) 10 (24.4)
 1 cm 12 (13.6) 10 (21.3) 2 (4.9)
Table 1. Patient characteristics in relation to the tumorigenicity of engrafted tumors in a xenograft model
Values are presented as number (%) unless otherwise indicated. CA-125, carbohydrate antigen 125; FIGO, The International
Federation of Gynecology and Obstetrics; LN, lymph node; ASA, American Society of Anesthesiologists; NGR, no gross
residual disease. 
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5. Statistical analyses
SPSS ver. 23.0 for Windows (IBM Corp., Armonk, NY) was
used to analyze data. The chi-square or Fisher exact tests
were used to compare engraftment status with patient char-
acteristics. Survival outcomes were determined through a
Kaplan-Meier survival analysis. Univariate and multivariate
analyses of the effects of various prognostic factors on sur-
vival were performed using the Cox proportional hazards
model. Multivariate analysis was performed with variables
that were considered significant in the univariate analysis.
p-values of less than 0.05 were considered statistically signif-
icant.
6. Ethical statement
This study was reviewed and approved by our Institu-
tional Review Board (IRB No. 4-2013-0526), and was per-
formed in accordance with the ethical standards described
in the Declaration of Helsinki. The requirement to obtain a
written informed consent was waived by the Institutional 
Review Board of the Yonsei University College of Medicine
because our study was retrospective research, and this 
research presented no more than minimal risk of harm to
subjects. All animal experiments were performed according
to protocols approved by the appropriate institutional 
review board and conducted in accordance with the National
Institutes of Health Laboratory Animal Research Guide for
the Care and Use ofLaboratory Animals.
Results
1. Patient characteristics and tumorigenicity 
Out of 88 tumor specimens, 49 (53.4%) were engrafted suc-
cessfully. Patient characteristics and comparisons according
to tumorigenicity are shown in Table 1. The patients had a
median age of 52 (range, 27 to 82), and 83% carried advanced
FIGO stage cancer. The subjects underwent one of two types
of treatment including primary debulking surgery (72.7%)
and interval debulking surgery (27.3%). Seventy-six patients
received optimal surgery that resulted in a residual tumor
size of less than 1 cm.
Variable No.
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age (yr) 88 1.013 (0.986-1.040) 0.360
FIGO stage
1-2 15 1 (reference) 1 (reference)
3-4 73 3.226 (1.034-10.469) 0.044 5.071 (1.170-12.608) 0.027
LN metastasis
Yes 41 1 (reference) -
No 43 1.712 (0.924-3.170) 0.087 - -
Lymphovascular invasion
Yes 40 1 (reference) -
No 48 1.619 (0.876-2.994) 0.124 - -
High-grade tumor
Yes 22 1 (reference) 1 (reference)
No 66 0.273 (0.108-0.719) 0.008 0.458 (0.231-0.909) 0.026
Residual disease
NGR 50 1 (reference) 1 (reference)
< 1 cm 26 2.113 (1.075-4.155) 0.030 1.936 (0.965-3.882) 0.063
 1 cm 12 1.869 (0.778-4.491) 0.162 1.485 (0.585-3.771) 0.405
Tumorigenicity
No 41 1 (reference) 1 (reference)
Yes 47 1.949 (1.353-3.140) 0.043 2.196 (1.123-4.292) 0.021
Table 2. Univariate and multivariate analyses of various factors for progression-free survival
HR, hazard ratio; CI, confidential interval; FIGO, The International Federation of Gynecology and Obstetrics; LN, lymph
node; NGR, no gross residual disease. 
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Tumorigenicity was correlated with a high-grade tumor,
lymphovascular invasion, and residual disease after debulk-
ing surgery. There were no significant differences between
the two debulking surgery groups according to tumorigenic-
ity and age, preoperative CA-125 levels, lymph node metas-
tasis, histology, and stage.
2. Clinical outcomes and tumor engraftment
Median follow-up period was 21 months, ranging 1 to 100
months. Univariate and multivariate Cox regression analyses
of progression-free survival (PFS) in all patients are shown
in Table 2. Multivariate analysis of PFS identified advanced
FIGO stage, high-grade tumor, and tumorigenicity as signif-
icant factors (p=0.270, p=0.026, and p=0.021, respectively).
The hazard ratio of tumorigenicity for PFS was 2.196 (95%
confidence interval, 1.123 to 4.292). 
A Kaplan-Meier survival analysis indicated an apparently
unfavorable PFS in the tumorigenicity-positive compared to
the tumorigenicity-negative group, although this difference
was not significant (p=0.097) (Fig. 1A). In the subgroup
analysis, positive tumorigenicity correlated significantly with
a poor PFS when compared with negative tumorigenicity
among patients who underwent primary debulking surgery
(p=0.044) (Fig. 1B). Among patients who underwent interval
debulking surgery, there was no difference in PFS regarding
tumorigenicity (Fig. 1B).
3. Germline DNA mutation spectra versus tumorigenicity
The spectra of germline mutations are presented in Fig. 2.
Six of 11 patients whose tumor samples engrafted success-
fully showed six pathogenic mutations. These included four
nonsense mutations in BRCA1 and BRCA2, and two splicing
mutations in BRCA1 and MUTYH. Three pathogenic muta-
tions were evident in three of eight patients whose tumor
samples failed to engraft. These three mutations were all
frame shifts in BRCA1, BRCA2, and RAD51D.
Discussion
We compared the clinical features and outcomes of 
patients with EOC in relation to successful tumorigenicity in
a xenograft model. Similar to previous studies [9,10], xeno-
grafts were established successfully with 53.4% of the pri-
mary tumors. Tumorigenicity of the grafted tumors corre-
lated with lymphovascular invasion and failure to achieve
optimal surgery. Successful tumor engraftment in the xeno-
graft model also appeared to be associated with high-grade
tumors. We observed an apparently unfavorable PFS in the
tumorigenicity-positive compared to the tumorigenicity-neg-
ative group, although this difference was not significant.
Specifically, in patients who underwent primary debulking
Fig. 1.  Comparison of progression-free survival in patients relative to the tumorigenicity of engrafted tumors in a xenograft
model. (A) Comparison in 88 patients. (B) Subgroup analysis by type of debulking surgery: primary and interval debulking.
PDS, primary debulking surgery; IDS, interval debulking surgery.
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surgery and whose tumors failed to engraft, there was sig-
nificant improvement in PFS. In addition, tumorigenicity
was an independent predictor of PFS. These results suggest
that EOCs with more aggressive features are better able to
engraft than less aggressive cancers.
In our study, tumorigenicity was significantly correlated
with PFS in chemotherapy-naïve cancer. This finding 
implied that engraftment failure of chemotherapy-naïve 
tumors reflected low aggressiveness of the primary tumor.
However, after cytotoxic chemotherapy had affected the can-
cer tissue, failure of tumor engraftment did not appear to
represent low aggressiveness of the primary tumor because
there was poor PFS regardless of tumorigenicity. This obser-
vation suggested that, after neoadjuvant chemotherapy, even
aggressive malignant cells could fail to engraft in the
xenograft model. Considering the high chemosensitivity of
EOC, neoadjuvant chemotherapy would greatly reduce the
tumor bulk. This may result in low cellularity of the tumor
sample obtained during debulking surgery [12]. In other
words, it appears that the low cellularity of the cancer spec-
imen, not the low aggressiveness of the primary tumor, 
resulted in the failure of engraftment.
Our results demonstrated that tumorigenicity could be
used as a strong predictive factor for aggressiveness of the
primary tumor regarding lymphovascular invasion, high-
grade, and failure in the achievement of optimal surgery. In
particular, because optimal debulking surgery is a major fac-
tor that impacts survival in advanced ovarian cancer [13],
tumor engraftment can act as a useful indicator of survival
outcome. In our study, there was a marginally significant 
improvement in PFS in the negative tumorigenicity group,
and significant improvement in the negative tumorigenicity
group treated with primary debulking surgery, indicating
the possible role of tumorigenicity as a predictive factor.
A few previous studies have evaluated the relationship 
between successful tumorigenicity in a xenograft model and
clinical outcomes of EOC patients [9,10]. In one study using
45 xenografts, patients whose tumors were successfully 
engrafted in mice had significantly inferior overall survival
when compared with those whose tumors failed to engraft
(p=0.040) [10]. In another study, 168 xenografts were ana-
lyzed. The authors reported that patients whose tumors suc-
cessfully engrafted in mice had inferior overall survival
(p=0.059) relative to patients whose tumors did not success-
fully engraft [9]. Comparable studies have been performed
for colon cancer, non-small cell lung cancer, breast cancer,
and uveal melanoma [3,11,14-16]. A study for non-small cell
lung cancer showed that tumorigenicity correlated with the
presence of KRAS mutations, poor differentiation, and larger
tumor size. In addition, tumorigenicity was an independent
predictor of shorter disease-free survival [14]. In contrast, 
another non-small cell lung cancer study reported that 
tumorigenicity did not correlate with clinical outcomes [15].
The previous studies on the correlation of engraftment in
xenograft models and clinical outcomes, however, did not
perform a subgroup analysis for investigating the possible
influence of cytotoxic chemotherapy on tumorigenicity.
Numerous genomic mutations have been identified in 
patients with EOC, and high levels of oncogene mutation can
accelerate tumor engraftment [17-19]. In our study, we per-
formed the next-generation sequencing assay and compared
the spectra of germline mutations relative to tumorigenicity
in the xenograft model. We detected several mutations of
EOC-related genes. Mutation of BRCA1 and BRCA2 were 
detected most frequently, especially among patients with suc-
cessful tumor engraftment. According to previous reports,
xenograft models can accurately represent the genetic diver-
Fig. 2.  Comparison of germline mutation spectra relative
to tumorigenicity using a 35-multigene panel next-gener-
ation sequencing assay. VOUS, variants of unknown sig-
nificance.
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sity of the primary tumor and better predict clinical tumor
response to new therapeutics, such as molecularly targeted
therapy [10,11]. Further studies that analyze somatic muta-
tions of our engrafted tumors could verify the utility of the
xenograft model for drug sensitivity testing followed by mol-
ecularly targeted therapy, especially those with disease 
refractory to conventional treatments [8,20].
Well-characterized xenograft models are useful in devel-
oping novel targeted therapies [21,22]. In the current study,
xenografts were stably established, and we observed that
successful tumorigenicity of patient-derived EOC specimens
correlated with more aggressive cancer features and worse
oncologic outcomes. Therefore, xenograft models may play
a role as effective preclinical tools to evaluate cancer progres-
sion and to determine treatment strategies. These models can
be applied to further pharmacologic and genomic research
on personalized therapies. Our results provide evidence that
xenograft models are relevant to EOC patients with a refrac-
table course or high risk of relapse. We expect that personal-
ized treatments with the preclinical use of xenograft models
will improve survival rates for EOC patients. 
In conclusion, our study showed that the successful tumo-
rigenicity of EOC specimens in a xenograft model was asso-
ciated with more aggressive disease and worse prognosis. In
particular, failure of chemotherapy-naïve tumor engraftment
indicated low aggressiveness of the primary tumor that
could result in a favorable prognosis. As a preclinical tool,
xenograft models may be helpful to predict disease progres-
sion for personalized treatment and, finally, to improve clin-
ical outcomes of EOC patients. Further pharmacologic and
genomic studies on personalized treatments using the
xenograft model are expected to provide novel treatments
for retractable EOC patients.
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